Advertisement

Search Results

Advertisement



Your search for it matches 15588 pages

Showing 4901 - 4950


leukemia

FDA Approves Oral Azacitidine as Maintenance Therapy for Adults With AML in First Remission

On September 1, the U.S. Food and Drug Administration (FDA) approved oral azacitidine (Onureg; also known as CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery...

lung cancer
immunotherapy

Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?

After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...

hematologic malignancies
covid-19

Are Patients With Hematologic Cancers More Vulnerable to the Effects of COVID-19?

A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that, compared with patients who have other malignancies, patients with blood cancers are more vulnerable to the effects of COVID-19 infection. These results were published by Lee et al in The Lancet Oncology. As...

prostate cancer
cardio-oncology

Metastatic Prostate Cancer: Sorting Through the Treatment Maze

The message still needs to get out that metastatic castration-sensitive prostate cancer should be treated with both androgen-deprivation therapy (ADT) and either docetaxel or an androgen receptor pathway inhibitor. In spite of “overwhelming” support for ADT plus abiraterone/prednisone,...

Expert Point of View: Misako Nagasaka, MD

The invited discussant of the ORIENT-11 trial, Misako Nagasaka, MD, a medical oncologist at Karmanos Cancer Institute, Wayne State University, Detroit, noted that, if approved, sintilimab will join a crowded list of first-line immuno-oncology agents for advanced non–small cell lung cancer,...

cost of care

Web-Based Tool May Help Patients With Cancer Choose the Best Insurance for Their Needs

Given the rising costs of cancer care, many patients with cancer and cancer survivors are challenged by financial toxicity, the burden of care costs. Many struggle to choose a health insurance plan that best meets their needs. Moreover, these challenges are often exacerbated by limited health...

integrative oncology

Acupuncture vs Sham Procedure and Usual Care for Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a debilitating and enduring adverse effect of many antineoplastic agents, which negatively impacts the quality of life of patients with cancer and survivors. Current pharmacotherapy has limited efficacy and causes undesirable effects. In this...

lung cancer
thyroid cancer

RET Inhibitor Selpercatinib Achieves Durable Responses in Majority of Patients With RET Gene Fusions

For patients with non–small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses in the majority of participants in the phase I/II LIBRETTO-001 trial, according to researchers from The University of...

breast cancer
survivorship

Breast Cancer Survival Is Significantly Decreased Among Premenopausal Women Previously Treated With Radiation for Childhood or AYA Cancer

Although radiotherapy is integral to the multidisciplinary therapy used in the treatment of common childhood and adolescent and young adult (AYA) cancers, including Hodgkin lymphomas, sarcomas, and breast cancer, the treatment is a strong risk factor for a secondary breast malignancy, especially...

From Behind the Iron Curtain to a Career in Gynecologic Cancer Research for Daniela Matei, MD

Daniela Matei, MD, Diana, Princess of Wales Professor of Cancer Research at Northwestern Feinberg School of Medicine, Chicago, grew up Sibiu, a picturesque Romanian city situated at the foothills of the Cindrel Mountains in historic Transylvania. “Both of my parents were physicians, and some of my ...

head and neck cancer

Transoral Robotic Surgery May Improve Outcomes in Early-Stage Oropharyngeal Cancer

Robotic surgery for patients with early-stage oropharyngeal squamous cell cancer may be associated with improved health outcomes, including better long-term survival, according to a study published by Nguyen et al in JAMA Oncology. Transoral robotic surgery is a minimally invasive procedure in...

pancreatic cancer

Sortilin May Be a Potential Therapeutic Target in Pancreatic Cancer

In a study published by Gao et al in The American Journal of Pathology, scientists reported the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells. The investigators speculated that this finding may lead to the development of more effective treatment for...

Sanjiv Sam Gambhir, MD, PhD, Pioneer in Molecular Imaging, Dies at 57

Sanjiv Sam Gambhir, MD, PhD, Professor and Chair of Radiology at the Stanford School of Medicine and an internationally recognized pioneer in molecular imaging, died on July 18, 2020, of cancer. He was 57. The Virginia and D.K. Ludwig Professor of Cancer Research, Dr. Gambhir dedicated his career...

Cornelius O. ‘Skip’ Granai, MD, Champion of Cancer Care for Women, Dies at 71

Cornelius O. “Skip” Granai, MD, Founder of the Program in Women’s Oncology at Women & Infants Hospital of Rhode Island, died on June 28, 2020, after a long bout with cancer. Dr. Granai strongly believed that cancer care for women should encompass both breast and gynecologic cancers, according...

Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy

Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...

breast cancer

One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy

Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...

solid tumors

Tumeur Fibro-Plastique

The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...

Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers

Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...

After Immigrating From India, Neha Vapiwala, MD, FACR, Followed Her Dream of a Career in Medicine

Neha Vapiwala, MD, FACR, Professor and Vice Chair of Education in the Department of Radiation Oncology and newly appointed Dean of Admissions at the Perelman School of Medicine at the University of Pennsylvania (UPenn), Philadelphia, was born in India to parents who aspired to emigrate to the...

integrative oncology

Ashwagandha

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present updated information on ...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia

The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...

covid-19

Managing Cancer in Older Adults During the COVID-19 Pandemic

The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...

cardio-oncology

Association of Community Cancer Centers Announces 2020 Innovator Award Recipients

The Association of Community Cancer Centers (ACCC) announced the winning programs for its 10th annual ACCC Innovator Awards, highlighting the year’s leading-edge strategies to challenges faced by oncology programs and practices across the country. The eight ACCC Innovator Award winners feature...

David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline

For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the...

multiple myeloma

How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome

The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...

cost of care

How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs

Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...

Rural Cancer Care: Models of Success and Barriers Highlighted in New State of Cancer Care in America Package

JCO Oncology Practice has published an article on rural cancer care as part of the State of Cancer Care in America series. “Closing the Rural Cancer Care Gap: Three Institutional Approaches” draws from data presented during the second State of Cancer Care in America live event as well as supporting ...

prostate cancer

BRCA Study: Clinic Is Saving Men’s Lives in Israel

Uriya, age 49, visits Israel’s Rabin Medical Center for a cancer screening. On the surface, he shows no signs of disease. However, results from a study by David Margel, MD, PhD, revealed Uriya is living with prostate cancer at an early yet curable stage. Uriya carries the BRCA gene. Rabin Medical...

issues in oncology

For Your Patients: An Expert Q&A on Cancer Disparities and Health Equity

Cancer does not affect all people equally. The phrase “cancer disparities” refers to the differences in the number of new cancer cases as well as differences in cancer outcomes that exist among different populations. Disparities more often negatively affect racial and ethnic minorities, poor...

leukemia
lymphoma

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...

skin cancer

Adding Immunotherapy to BRAF/MEK Inhibition in BRAF V600–Mutant Melanoma: First Step on the Journey

As investigators, we were always determined to find the drug to work with BRAF/MEK inhibitor combination therapy. It had come on like a storm and showed us that we could help even those with the most advanced metastatic melanoma, as long as it harbored the magical BRAF V600E mutation.1...

immunotherapy

The Parker Institute for Cancer Immunotherapy Appoints John Connolly, PhD, as Chief Scientific Officer

The Parker Institute for Cancer Immunotherapy (PICI) announced that John Connolly, PhD, has been named Chief Scientific Officer. In this role, Dr. Connolly will design and execute PICI’s overall research strategy in close collaboration with the institute’s leadership team, center directors, and...

skin cancer
immunotherapy

Researchers Outline Need for Evaluation of Gene-Expression Profiling in Melanoma

A consensus statement published in JAMA Dermatology by an international group of melanoma researchers evaluated the use of prognostic gene-expression profile testing to guide clinical management of melanoma.1 The group cautioned against the routine use of currently available gene-expression...

hematologic malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz...

Raymond N. DuBois, MD, PhD, Named Director, MUSC Hollings Cancer Center

The Medical University of South Carolina (MUSC) President David J. Cole, MD, FACS, has announced the appointment of MUSC College of Medicine Dean Raymond N. DuBois, MD, PhD, to the additional role as Director of the MUSC Hollings Cancer Center. Dr. DuBois has headed the College of Medicine for more ...

Bert W. O’Malley, Jr, MD, Named President and Chief Executive Officer of the University of Maryland Medical Center

Following an extensive national search, Bert W. O’Malley, Jr, MD, has been appointed as the new President and Chief Executive Officer of the University of Maryland Medical Center (UMMC), the flagship academic hospital for the University of Maryland Medical System and an anchor institution in...

lymphoma
immunotherapy

Tafasitamab-cxix in the Treatment of Diffuse Large B-Cell Lymphoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 31, 2020, tafasitamab-cxix, a CD19-directed...

covid-19

Repurposing Drugs for the Treatment of COVID-19

A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...

gastrointestinal cancer

Switch Control Inhibitor for GISTs Harboring Drug-Resistance Mutations: The INVICTUS Trial

In May 2020, the U.S. Food and Drug Administration (FDA) approved ripretinib for patients who have received prior treatment with three or more kinase inhibitors, including imatinib, for advanced gastrointestinal stromal tumors (GIST). The approval was largely based on the findings of the...

covid-19

Impact of Immune Checkpoint Inhibitors on COVID-19 in Patients With Cancer

In the time of COVID-19, there is much to learn about the intersection of coronavirus and cancer. One area of concern has been whether immunotherapies increase the risk of mortality in patients with cancer who also have COVID-19 infection. “To what extent immune checkpoint inhibition affects...

covid-19

Reevaluating the Delivery of Palliative Care in the Era of COVID-19

Palliative care services are so crucial to the well-being of patients with cancer that, in 2017, ASCO updated its clinical practice guideline on the integration of palliative care into standard oncology care.1 The updated guideline recommends that all patients with advanced cancer receive dedicated ...

lymphoma

Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas

As chemotherapy and chemoimmunotherapy regimens reach their maximal impact in follicular lymphoma and mantle cell lymphoma, clinicians are turning to chemotherapy-free approaches to achieve better control, less toxicity, and (hopefully) a cure. During the ASCO20 Virtual Education Program, Sonali M. ...

Pet Therapy: How the Cat I Never Wanted Saved My Life

My husband and I adopted our cat, Franklin, on a cold November day. It was one of the last days Andrew felt well enough to leave the house to go anywhere other than to chemotherapy or a doctor’s appointment. Our news at these appointments had shifted toward the negative, with disease progression...

health-care policy

Past CMS and FDA Head Discusses Challenges in U.S. Health-Care Policy and Possible Solutions

As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on some of the large-scale public health and...

pancreatic cancer

ASCO Updates Metastatic Pancreatic Cancer Guideline

ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations.1 Last updated in 2018, this new version was triggered by novel evidence related to targeted...

immunotherapy
lung cancer
cns cancers
leukemia
lymphoma

FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for a novel dosing regimen for durvalumab as well as for trilaciclib in small cell lung cancer; granted Fast Track designations to treatments for glioblastoma and B-cell acute lymphoblastic leukemia; and issued reports...

breast cancer
covid-19

Study Finds Treatment Delays for Patients With Breast Cancer Early in the COVID-19 Pandemic

The results of an online questionnaire of 609 breast cancer survivors in the United States suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. The study was published by Papautsky et al in the journal Breast Cancer Research and ...

covid-19

Updated Registry Data Confirm Higher COVID-19–Related Mortality in Patients With Cancer

“The distressing intersection of COVID-19 and cancer requires the use of large registries to acknowledge diversity,” stated Solange Peters, MD, PhD, President of the European Society for Medical Oncology (ESMO), in her keynote speech at the American Association for Cancer Research (AACR) Virtual...

solid tumors

Tumor Mutational Burden and the Future of Complex Biomarkers

The development of complex biomarkers such as tumor mutational burden (TMB) has enabled clinicians to identify patients more likely to respond to treatment of a variety of cancers, leading to more accurate diagnoses and improved outcomes. Differences in testing assays, however, have produced...

breast cancer
genomics/genetics

Three Novel Genetic Variants Linked to Male Breast Cancer Discovered

Scientists have newly discovered three genetic changes that increase the risk of breast cancer in men. These findings were published by Maguire et al in the Journal of the National Cancer Institute. The researchers identified three common variations in DNA that predispose men to developing breast...

Advertisement

Advertisement




Advertisement